business
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
Key takeaways
- RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) Jeff Lewis Thu, June 4, 2026 at 11:49 PM GMT+7 2 min read NBIX Neurocrine Biosciences, Inc.
- 15 Most Promising Stocks to Buy Right Now.
- On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc.
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) Jeff Lewis Thu, June 4, 2026 at 11:49 PM GMT+7 2 min read NBIX Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the
15 Most Promising Stocks to Buy Right Now.
On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $183 from $180 and maintained an Outperform rating on the shares. RBC said the stock has rebounded after a strong Q1, though concerns remain that Crenessity uptake could hit a near-term ceiling. RBC also said its endocrinologist survey suggests room for near- and long-term growth, including expected utilization growth among doctors not currently using the drug.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
UBS raises STMicroelectronics price target to €80 on growth drivers
Investing.com
Truist raises Snowflake stock price target on AI momentum
Investing.com
Benchmark raises CrowdStrike stock price target to $780 on AI demand
Investing.com
BNP Paribas Exane raises Broadcom stock price target to $640
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop